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A B S T R A C T  
 
The continuing spread of Multidrug-Resistant Tuberculosis (MDR-TB), which is defined as TB that 
shows resistance to both isoniazid and rifampicin, become one of the most urgent and difficult 
challenges in TB control. In Indonesia, the estimated total DR-TB case incidence of 24,000 or 
8.8/100,000 population (2.4% of total new TB patients). The first-ever MDR-TB treatment guideline 
published by WHO required a long duration (up to 20–24 months) and contained toxic second-line 
drugs with less effective & unfavorable outcomes. About ten years ago, a short regimen lasting 
nine instead of 20 months, called “Bangladesh regimen”, revolutionized MDR-TB treatment. The 
advent of rapid molecular diagnostic tests, discoveries of new and repurposed drugs, promising 
results based on trials and meta-analysis had prompted WHO to update its guidelines. Notably, 
drugs such as bedaquiline and clofazimine are now strongly recommended for the treatment of 
MDR-TB. At the same time, older injectables drugs have been downgraded due to poor 
effectiveness and side-effect profiles. In 2019, based on the programmatic data from the shorter 
all-oral bedaquiline-containing regimen implemented routinely in South Africa, WHO revised its 
recommendations on the use of a standardized shorter regimen. Based on the analysis, WHO 
affirmed its conditional recommendation for the shorter all-oral bedaquiline-containing MDR -TB 
regimen to be offered as a treatment option to MDR -TB patients who satisfy the eligibility criteria. 
The implementation of this all-oral shorter regimen is expected to improve the programmatic 
management of the MDR-TB worldwide. 
 




I N T R O D U C T I O N 
Until now, TB is still a major public 
health problem worldwide, despite the 
implementation of control measures using the 
DOTS (Directly Observed Treatment Strategy) 
in many countries since 1995. [1,2] The current 
standard antituberculosis chemotherapy 
treatment regimen currently recommended by 
the World Health Organization (WHO) consists 
of a 2-month intensive phase with isoniazid, 
rifampin, pyrazinamide, and ethambutol, 
followed by a 4-month continuation phase 
with isoniazid and rifampin. [3,4]  
Inappropriate or incorrect use of 
antimicrobial drugs can cause drug resistance, 
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which can then be transmitted, especially in 
crowded settings such as prisons, hospitals 
and densely-populated slums settlements. 
Multidrug‑resistant tuberculosis (MDR‑TB) is a 
disease caused by Mycobacterium tuberculosis 
that is resistant to at least both rifampicin and 
isoniazid with or without resistance to other 
anti-TB drug, which are practically incurable 
by standard first-line treatment. [2,5,6] 
 In 2017 there were around 558,000 
new cases rifampicin-resistant TB (RR-TB), 
nearly half of which were in three countries, 
namely India (24%), China (13%), and Russia 
(10%). Among RR-TB cases, an estimated 82% 
of these cases were MDR-TB. Globally, 3.6% of 
new TB cases and 17% of retreating TB cases 
were MDR/RR-TB cases. In Indonesia, the 
estimated DR-TB is 2.4% of the total new TB 
patients and 13% of previously treated TB 
patients with an estimated total DR-TB case 
incidence is 8.8/100,000 population. [2,7,8] 
Patients with MDR-TB require 
treatment regimens which are longer, less 
effective and less accessible than first-line 
regimens, but more costly, toxic and 
complicated to deliver. Most second-line MDR-
TB regimens in recent decades were designed 
to last ≥ 20 months, presenting a dreadful 
challenge to health service providers to ensure 
patient adherence and cure rates. [7,9]  Due to 
this long duration of MDR-TB conventional 
regimen treatment and side effects of the 
drugs, many patients failed to complete the 
treatment or stopped the treatment before 
completion. In 2019, of the estimated 465,000 
DR-TB patients worldwide, only 206,030 were 
found and 177,099 (86%) were treated, with a 
global treatment success rate of 57%. Data in 
Indonesia shows that there was declining in 
success rate of DR-TB treatment, starting from 
52.6% in 2009 to 39.2% in 2017. [8,10]  
Several studies were conducted to 
shorten the duration of regimen for MDR-TB. In 
2014, Aung, et al. through Damien Foundation 
Projects in Bangladesh, published a successful 
‘9-month Bangladesh regimen’ for MDR-TB 
among over 500 consecutive patients. [11,12] 
Based on the available evidence, in May, 2016, 
a standardized regimen of 9 to 12-month 
duration for MDR-TB was recommended by 
WHO, with moxifloxacin replacing gatifloxacin 
(originally used in the Bangladesh regimen). 
This shorter regimen reported to give relapse-
free cure in more than 85% of selected 
(eligible) MDR-TB patients. [9,10,12–14]  
 Since the first-ever MDR-TB treatment 
guideline published by WHO, the treatment 
and management of DR-TB has evolved 
significantly with the advent of rapid 
molecular diagnostic tests, new and 
repurposed drugs. In 2019, the programmatic 
data from the shorter all-oral bedaquiline-
containing regimen implemented routinely in 
South Africa prompted WHO to revise its 
recommendations on the use of a 
standardized shorter regimen. [7,15–17]  
Through this article, we will 
comprehensively discuss more about the 
implementation of the newest 
recommendation of shorter all-oral 
bedaquiline-containing MDR-TB regimen 
treatment in Indonesia. 
 
Types & Causes of TB Drug Resistance  
 Drug resistance can be primary or 
acquired. That is, someone may have primary 
infection transmitted directly from a person 
with DR-TB infection, or a patient may have a 
history of prior drug-susceptible TB with 
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subsequent development of acquired drug 
resistance. [1]  Based on the results of the anti-
tuberculosis drug sensitivity test, TB patients 
can be classified as mentioned in Table 1. [5,8,18]
 
Table 1. Types of TB Drug Resistance [18,19] 
Types Definition 
Mono-resistant TB  TB caused by an isolate that shows resistance to a single first-line anti-TB drug 
(isoniazid, rifampicin, ethambutol, or pyrazinamide) 
Isoniazid-resistant 
TB  




TB caused by an isolate that shows resistance to rifampicin, but is susceptible to 
isoniazid. 
Poly-resistant TB  TB caused by an isolate that is resistant to more than one anti-TB drug, but not 
resistant to both isoniazid and rifampicin simultaneously. 
Multidrug-resistant 
TB (MDR-TB)  
TB caused by an isolate that shows resistance to at least isoniazid and rifampicin. 
Pre-extensively 
drug-resistant TB 
(Pre XDR-TB)  
TB caused by an isolate that shows resistance to isoniazid, rifampicin, and either 





A rare type of MDR-TB that is resistant to isoniazid and rifampicin as well as to any 
fluoroquinolone and at least one out of the three injectable agents (amikacin, 
kanamycin, or capreomycin). Approximately 9% of the MDR-TB patients have 
extensively drug-resistant TB. 
 
 Drug resistance is a biological 
phenomenon that has been observed in 
Mycobacterium tuberculosis since the 
discovery of the first anti-TB drug, 
streptomycin. Many patients who were 
injected with streptomycin were brought from 
the brink of death and their sputum became 
temporarily clear of M. tuberculosis. But 
despite continuing to receive treatment, they 
soon began to excrete bacilli that were 
resistant to streptomycin in the laboratory. 
With the advent of new drugs —thioacetazone 
and para-aminosalicylic acid in 1948 and 
isoniazid in 1952— it became clear that 
combination chemotherapy was the key to 
preventing the development of resistance. [5] 
 Outbreaks of MDR-TB were initially 
thought to be driven by nosocomial 
transmission, particularly among HIV-positive 
patients. One of the largest and best-
documented outbreaks occurred in New York 
in the late 1980s and early 1990s. As Drug 
Sensitivity Testing (DST) laboratory capacity 
improved in resource-limited settings and 
global drug-resistant TB surveillance efforts 
grew, it became clear that MDR-TB was 
increasingly common throughout the world 
and a growing threat to the general public 
health. Clinically significant drug resistance 
usually emerges after 1 to 3 months of 
administration of an inadequate drug 
regimen. The causes of the global spread of 
MDR-TB include the following: [5,20] 
• Chaotic treatment. Improper use of anti-
tuberculosis drugs contributes to the 
development of drug resistance. Several 
factors related to this condition, such as: 
medicines are not taken as recommended 
due to incorrect knowledge, sub-optimal 
dosage of the drug, discontinue of 
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medication due to side effects/ pregnancy/ 
other condition, use of anti-tuberculosis 
without standardized supervision. 
• Amplifier effect of short-course 
chemotherapy. Drug resistance was 
developed from the repeated use of short-
course of chemotherapy in many parts of 
the world that do not have the resources to 
diagnose or treat drug-resistant TB 
correctly. 
• Community transmission. Current models 
indicate that in most countries, the 
majority of MDR-TB patients were infected 
initially with an MDR-TB strain, rather than 
slowly acquiring resistance caused by 
inadequate or irregular treatment. 
• Facility-based transmission. Nosocomial 
transmission in busy, crowded hospitals 
and health centres is likely an important 
driver of the epidemic, especially in high 
HIV prevalence settings. This can result in 
the spread of drug-resistant strains among 
patients receiving therapy for drug-
susceptible TB as well as to the health-
workers. 
Risk Assessment & Diagnosis of Multidrug 
Resistant Tuberculosis 
Rapid molecular testing for drug 
resistance should be performed if TB patients 
show 1 or more of characteristics as described 
in Table 2. Successful diagnosis and treatment 
of MDR-TB are based on a rapid and precise 
drug sensitivity test (DST), which provides 
evidence for selecting an effective drug. DST is 
divided into phenotypic tests that observe 
growth or metabolic inhibition in anti-TB drug-
free and drug-containing media; and 
molecular tests that detect genes related to 
drug resistance. Conventional phenotypic DST 
is a solid culture-based method that uses egg-
based or agar-based media (Lowenstein 
Jensen/ LJ media). These methods are 
sensitive, have good clinical correlation, and 
enable the determination of minimal 
inhibitory concentration. However, it takes a 
relatively long time as long as 3 to 8 weeks to 
confirm the results due to the long turnaround 
time for MTB culture. [8] 
Liquid culture (Mycobacteria Growth 
Indicator Tube/ MGIT) and DST have a higher 
rate of MTB isolation and require less time for 
detection than solid culture (1-2 weeks) and 
DST. However, it is more expensive and carries 
a risk of increased bacterial contamination 
and cross infection by nontuberculous 
mycobacterial isolation. [5,18] Indonesia has 
established Standardized Drug Susceptibility 
Test Packages (SDP) to be used since 
September 2019 to test the sensitivity of M. 
tuberculosis to several types of drugs including 
high-dose isoniazid, high-dose moxifloxacin, 
bedaquiline, linezolid, clofazimine, amikacin, 
delamanid, pyrazinamide. [8,21] 
Table 2. Characteristic suspicious for DR-TB [8,20] 
• Lack of conversion of cultures to negative 
during the first 3 months of therapy  
• Lack of improvement or only partial 
improvement in TB symptoms 
• Worsening of TB symptoms or radiograph 
findings despite TB treatment  
• Non-adherence or intermittent or erratic 
ingestion of prescribed anti-TB regimen  
• Lack of directly observed therapy (DOT) or 
poorly supervised therapy  
• Documented treatment failure or relapse 
• History of non-standard TB treatment 
regimen, including: administration of single-
drug therapy, inadequate drug dosing, use 
quinolones and second-line injection drugs 
for at least 1 month 
• Exposure to a person with documented 
drug-resistant TB  
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• Exposure to an individual highly suspected 
of having drug-resistant TB, including those 
who have received more than one course of 
TB treatment, prolonged treatment or who 
had a delayed response to treatment. 
 Molecular DSTs have been developed 
to offer an advantage over conventional 
phenotypic tests that are more time-
consuming. These tests can be used to 
diagnose TB through amplification of nucleic 
acids. They detect drug resistance by 
identifying genetic mutations in specific 
genes. These genotypic tests are more rapid 
and accurate than the phenotypic DSTs. There 
are two types of molecular DST that available 
in Indonesia. [5,18] 
• Rapid molecular test using Xpert MTB/RIF. 
The Xpert MTB/RIF is a fully automated real-
time PCR based molecular assay for 
detecting MTB and resistance to rifampicin 
coded by rpoB gene, which provides results 
within 2 hours. In a large clinical trial, this 
rapid molecular test showed an MTB 
detection accuracy of 98.2% in smear-
positive and culture-positive patients. The 
specificity of the Xpert MTB/RIF was 99.2%. 
[8,18] 
• Line Probe Assay (LPA). LPA is one of the 
sensitivity tests with genotypic methods. 
First-line LPA can detect resistance to 
rifampicin (rpoB), isoniazid (inhA and katG) 
and ethionamide/ prothionamide (inhA), 
while second-line LPA detects resistance in 
fluoroquinolone (gyrA and gyrB) and 
second-line TB injection drugs (eis and rrs). 
The results of the examination can be 
obtained in approximately 48 hours. [8] 
 
Treatment of MDR-TB with All-Oral 
Bedaquiline-containing Shorter Regimen 
 
Eligibility Criteria 
In eligible patients under 
programmatic conditions in South Africa, the 
shorter all-oral bedaquiline-containing 
regimen showed better efficacy than the 
previously recommended longer MDR-TB 
regimens without new drugs, and an 
injectable-containing shorter regimen with a 
lower likelihood of loss to follow-up. However, 
it is important to select the right patients to 
receive this MDR-TB regimen. The diagnostic & 
treatment algorithm for DR-TB in Indonesia is 
presented in Figure 1. The regimen may be 
offered to patients with confirmed MDR/RR-TB 
(with at least confirmed resistance to 
rifampicin), in the following situations: [8,16,22] 
• resistance to fluoroquinolones has been 
ruled out; 
• no contact with Pre-XDR/ XDR-TB patient; 
• no resistance or suspected ineffectiveness 
of a medicine in the shorter regimen 
(except isoniazid resistance with mutation 
affected inhA or katG genes); 
• no exposure to previous treatment with 
second-line ATDs in the regimen for more 
than 1 month (unless susceptibility to these 
medicines is confirmed); 
• no extensive pulmonary TB disease and no 
severe extrapulmonary TB;  
• not pregnant;  
• children 6 years old and above. 
Drug Composition & Duration of the Regimen 
The duration of treatment and the dosage of 
anti TB drugs used in this regimen are shown 
in Table 3 & Table 4, respectively.
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Table 3.  Duration of Treatment & Drug Composition of All-Oral Bedaquiline-containing MDR-TB Regimen [8,16] 
    
Drug Name 
Initial Phase 




Bedaquiline (Bdq) * √ 
6 months (regardless of the 
duration of the initial phase) 
Levofloxacin (Lfx) or 
Moxifloxacin (Mfx) 
√ √ 9-11 months 
Clofazimine (Cfz) √ √ 9-11 months 
High Dose Isoniazid (HHD) √ - 4-6 months 
Pyrazinamide (Z) √ √ 9-11 months 
Ethambutol (E) √ √ 9-11 months 
Ethionamide (Eto) √ - 4-6 months 
*) Bedaquiline (Bdq) is administered with a fixed duration of 6 months, regardless of the duration of the initial 
phase (even though the initial phase of treatment is only for 4 or 5 months, Bedaquiline remains administered 
for 6 months). 
**) The duration of the initial phase depends on the time of AFB conversion needed. The definition of AFB 
conversion is when microscopic test results or sputum culture changes from positive to negative on 2 
consecutive tests with an interval of 30 days. The first negative test result is the conversion time. 
 




Body weight (for patient aged ≥ 15 yo) 
30-35 kg 36-45 kg 46-55 kg 56-70 kg >70 kg 
Bedaquiline (Bdq) * tablet 100 mg 
4 tablets/ day (first 2 weeks) continue with 2 tablets/ day (3 times 
a week) for the rest of 22 weeks 
Levofloxacin (Lfx) 
tablet 250 mg 3 3 4 4 4 
tablet 500 mg 1.5 1.5 2 2 2 
Moxifloxacin (Mfx) tablet 400 mg 
1 1 1.5 1.5 1.5 
1 or 1.5 1.5 1.5 or 2 2 2 
Clofazimine (Cfz) 
capsule 50 mg 2 2 2 2 2 
capsule 100 mg 1 1 1 1 1 
Ethambutol (E)  tablet 400 mg 2 2 3 3 3 
Pyrazinamide (Z) 
tablet 400 mg 3 4 4 4 5 
tablet 500 mg 2 3 3 3 4 
Ethionamide (Eto) tablet 250 mg 2 2 3 3 4 
Isoniazid (HHD) tablet 300 mg 1.5 1.5 2 2 2 
*) Bedaquiline (Bdq) is administered by swallowing 1x4 tablets @ 100mg every day in the first 2 weeks and continue with 1x2 
tablets @ 100mg (thrice a week/ every Monday, Wednesday & Friday) for the rest of 22 weeks. 
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The principles of administration of 
shorter all-oral MDR-TB treatment regimen 
are: [8,23] 
• Before treatment started, it is 
recommended to wait for the results of the 
drug sensitivity test to fluoroquinolone 
(second-line LPA results), but if LPA results 
are not available until day-7, treatment 
should begin immediately and the 
selection of treatment regimen is based on 
the results of anamnesis and previous 
history of TB/ DR-TB treatment. 
• The total duration of treatment is 9–11 
months, with an initial phase of 4 months 
(in case of conversion of AFB on or before 
the 4th month) and a continuation phase for 
5 months. Patients with a negative result of 
initial AFB or culture test may be given an 
initial phase for 4 months. Clinical and 
radiological conditions should be 
monitored to ensure improvement occurs. 
• If there is no AFB conversion at the 4th 
month, the initial phase of treatment can 
be extended to the 5th or the 6th month 
(depending on the time of AFB conversion). 
Second-line LPA examination and DST 
should be repeated if the AFB test results in 
the 4th month are still positive. 
• If there is no AFB conversion at the 6th 
month of treatment, this treatment 
regimen should be discontinued and the 
patient's treatment result is recorded as 
"treatment failure". The patient is re-
enrolled or referred for an individualized 
longer MDR-TB treatment regimen. The 
treatment regimen administration are 
shown schematically in Figure 2. 
• All medications in the regimen are taken 
once a day, 7 days a week (daily), except for 
bedaquiline is taken daily in the first 2 
weeks and 3x a week in the next 22 weeks 
(total Bdq is taken for 24 weeks). 
• The composition of this treatment regimen 
is fixed and cannot be modified. But under 
certain conditions, such as the occurrence 
of side effects, ethionamide can be 
replaced with prothionamide and 
levofloxacin replaced with moxifloxacin. 
• This treatment regimen cannot be 
administered when the results of first-line 
LPA indicate the presence of mutations in 
the inhA and katG genes simultaneously, 
indicating resistance to high-dose INH and 
ethionamide/prothionamide. 
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Figure 1. Diagnostic & Treatment Algorithm for DR-TB in Indonesia [8,23] 
Figure 2. Shorter All-Oral MDR-TB Treatment Regimen Administration Scheme [8] 
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Monitoring of Treatment 
 Before starting the treatment, MDR-TB 
patient candidates for the shorter regimen 
need to undergo various initial examinations 
to determine their initial condition. Patients 
who receive a shorter MDR-TB treatment 
regimen need to be monitored during 
treatment using schedules of relevant clinical 
and laboratory testing. Even though the 
shorter all-oral bedaquiline-containing 
regimen is well tolerated, the safety profile of 
some medicines used concomitantly may 
present its own concerns. Any adverse events 
for patients on treatment need to be reported 
primarily to the national agency responsible 
for pharmacovigilance. All details of the 
patient’s diagnosis, DST, treatment, adverse 
effects and outcomes must be recorded in 
accordance with good practice. [7,8,16] Detailed 
information on monitoring program for this 
regimen is presented in Appendix.  
 
The Use of Bedaquiline in the Newest 
Shorter All-Oral MDR-TB Treatment 
Regimen 
Bedaquiline, formerly known as 
TMC207 or R207910, is a new antibiotic 
belonging to the class of diarylquinolines 
developed by Janssen Pharmaceuticals 
(Titusville, NJ, USA) with specific activity 
against M. tuberculosis, which has also shown 
in-vitro activity against other non-tuberculous 
mycobacteria. Some of the preclinical studies 
were conducted in guinea pigs in which 
bedaquiline was administered for 6 weeks and 
found to be effective in the eradication of M. 
tuberculosis from both primary and secondary 
lesions in lung granuloma. In mice, the 
combination of bedaquiline–rifapentine–
pyrazinamide produces significant 
bactericidal activity. [24,25] 
 Bedaquiline (molecular weight 555.50 
Da) is an antibiotic compound with a 
quinolinic central heterocyclic nucleus with 
alcohol and amine side chains that are 
responsible for the compound’s anti-
mycobacterial activity (Figure 3). Bedaquiline 
was discovered after a high-throughput 
evaluation of thousands of compounds using 
Mycobacterium smegmatis in a whole-cell 
assay. The mode of action of bedaquiline is by 
inhibiting the ATP synthase of M. tuberculosis, 
which was a completely new target of action 
for an antimycobacterial drug. Mycobacterium 
tuberculosis requires mycobacterial adenosine 
triphosphate (ATP) synthase to synthesis ATP. 
Bedaquiline inhibits the enzyme 
mycobacterial ATP synthase and prevents the 
ATP synthesis in bacteria leading to bacterial 
death. Bedaquiline specifically binds to 
subunit C of the mycobacterial ATP synthase 
enzyme. The gene which encodes the C 
subunit of the enzyme is atpE. Any mutation in 
this gene can alter the effect of bedaquiline. 
There was a synergistic interaction between 
pyrazinamide and bedaquiline as 
pyrazinamide being indirect an inhibitor of 
ATP synthase. [24–26] 
 
Figure 3. Molecular Structure of Bedaquiline as the 
Free Base Form [26] 
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 After 50 years, this new anti-
tuberculosis drug with a different mechanism 
of action was approved as a part of 
combination therapy in adults with MDR-TB 
for its bactericidal activity over M. tuberculosis. 
The drug was approved under an accelerated 
procedure by the US Food and Drug 
Administration (USFDA) in December 2012 and 
conditionally approved by the European 
Medicines Agency (EMA) in February 2014. In 
June 2013, the WHO issued interim policy 
guidance on the use of bedaquiline in the 
treatment of MDR-TB. [27,28] 
 Initially a dose-finding study was 
carried out to investigate the early bactericidal 
activity, safety, tolerability and 
pharmacokinetics of bedaquiline. 
Subsequently, the phase II C208 trial focusing 
on MDR-TB enrolled 47 patients that were 
randomly assigned to either placebo or 
bedaquiline. A higher culture conversion rate 
was observed among 23 patients who took 
(TMC207) bedaquiline 400 mg daily for 2 weeks 
followed by 200 mg three times a week for 6 
weeks. The second stage of the same study 
(C208 stage 2) was a Phase IIb, randomised, 
multicentre double-blind, placebo-controlled 
study that involved 160 subjects. A significant 
reduction in the time of sputum smear and 
culture conversion among 79 patients treated 
with bedaquiline was noted. A systematic and 
critical analysis of the evidence regarding 
bedaquiline and MDR-TB was performed by 
Pontali, et al. in 2016. [24,29] The resume of 
several clinical studies on bedaquiline and the 
highlighted findings are listed in Table 5.  
In 2018, WHO convened a Guideline 
Development Group (GDG) to update its policy 
recommendations on the treatment of 
MDR/RR-TB, which revised its ranking of 
medications for MDR/RR-TB based on 
effectiveness. The new ‘Group A’ medicines 
(all-oral medications) to be prioritized 
included levofloxacin (Lfx)/ moxifloxacin (Mfx), 
bedaquiline (Bdq), and linezolid (Lzd), while 
injectable aminoglycoside (IA) was demoted to 
‘Group C’ status, to be included only when 
better options are unavailable. Injectable 
agents are no longer among the priority 
medicines when designing longer MDR-TB 
regimens, with kanamycin and capreomycin 
not recommended any more. [30,31]  
Since then, all-oral regimens became 
the preferred option for treating MDR-TB 
patients, with three medicines including 
fluoroquinolones (levofloxacin/ moxifloxacin), 
bedaquiline and linezolid are strongly 
recommended to be used in a longer regimen, 
and completed by other medicines ranked by 
a relative balance of benefits to harms. 
Subsequently, a revised recommendation on 
the use of a shorter MDR-TB regimen was 
released, included a recommendation to 
replace the IA used in the previous 2016 
shortened regimen guideline kanamycin (or 
capreomycin), with amikacin. As debate about 
the excessive adverse effects of injectable 
agents (especially hearing loss) became more 
prominent, and new & repurposed oral anti-TB 
drugs became available, the evaluation of new 
evidence on injectable-free shorter regimens 
from programmatic settings became pivotal. 
In June 2018, the South African National 
Department of Health (NDOH) made a decision 
to make bedaquiline routinely available to all 
MDR/RR-TB patients. South Africa became the 
first country to recommend an injection-free, 
all-oral short-course (9–12 month) regimen, 
which bedaquiline used to replace the 
injectable aminoglycoside. [7,30,32]
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Table 5. Clinical Studies on Bedaquiline [29] 
Author, year 
Type of study 
(Subjects taking Bdq, n) 
Highlighted findings 




Efficacy findings: Bedaquiline reduced the time to conversion to a 
negative sputum culture; Bedaquiline increased the proportion of 
patients with conversion of sputum culture 
Tolerability findings: Most AEs were mild to moderate; only nausea 
occurred significantly more frequently in the bedaquiline group 




Efficacy findings: Bedaquiline reduced the median time to culture 
conversion from 125 days to 83 days 
Tolerability findings: Bedaquiline had similar rates of AEs, treatment-
related AEs, and AEs leading to study discontinuation than placebo; 
the most frequent AEs were nausea, arthralgia and vomiting; the 
severity of most adverse events was grade 1 or 2 
Guglielmetti, et al., 
2015 
Retrospective cohort study 
(35) 
Efficacy findings: Culture conversion rate was 97% after 6 months of 
therapy 
Tolerability findings: Mild liver enzyme elevation (⩾2-fold from 
baseline) was reported in 14% of patients, and a ⩾5-fold increase 
occurred in two additional patients (6%); confounding effect of 
concomitant drugs was mentioned 
Ndjeka, et al., 2015 Interim cohort analysis 
(91 (54 HIV+) 
Efficacy findings: In total, 48 (76%) out of 63 patients with 6 months 
of follow-up either achieved culture conversion or remained culture-
negative 6 months after initiation of bedaquiline 
Tolerability findings: Good profile 





Efficacy findings: Culture conversion was 72.2% at 120 weeks, and 
73.1%, 70.5% and 62.2% in MDR-TB, pre-XDR-TB and XDR-TB patients, 
respectively 
Tolerability findings: The commonest AEs were similar to those 
generally reported in MDR-TB treatment cohorts; most were grade 1 
or 2; hyperuricaemia and increased aspartate aminotransferase were 
the most frequent grade ⩾3AEs; the incidence of AEs was highest 
during the first 12 weeks; serious AEs were reported in 47 (20.2%) 
patients: respiratory infections/ disorders were the most common 
 
 In 2019, evidence review was 
performed by WHO, based primarily on 
programmatic data from South Africa 
recorded in the Electronic Drug-Resistant 
Tuberculosis Register (EDRWeb) and 
secondary comparative analyses were carried 
out using global dataset of the records of 
individual patients who have been treated for 
MDR/RR-TB (as of November 2019, it contained 
13,273 records from 55 studies or centres in 38 
countries overall). Based on the analysis, WHO 
affirmed its conditional recommendation for 
the shorter all-oral bedaquiline-containing 
MDR/ RR-TB regimen to be offered as a 
treatment option to MDR/RR-TB patients who 
satisfy the eligibility criteria. [7,16] 
The most frequent adverse drug 
reactions (observed in >10% of patients) 
during treatment with bedaquiline in the 
controlled trials were nausea, arthralgia and 
headache. Nevertheless, one key issue related 
to safety and tolerability remain open, which is 
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the QTc prolongation. In the first studies the 
QT increase from baseline in the bedaquiline 
group persisted even after the drug was 
discontinued.   In   addition, co-administration 
of bedaquiline and drugs causing QTc 
prolongation (e.g., fluoroquinolones and 
clofazimine) showed an additional effect in 
most studies. Based on this argument, WHO 
recommended the co-administration of those 
drugs should occur following the guideline 
recommendations (having met specific 
criteria) and closely monitored patient’s ECG 
within the treatment program. [17,29] 
 
CONCLUSION 
 In 2019, the programmatic data from 
the shorter all-oral bedaquiline-containing 
regimen implemented routinely in South 
Africa prompted WHO to revise its 
recommendations on the use of a 
standardized shorter regimen. A total of 10,152 
records of patients with MDR/RR-TB initiating 
TB treatment at any time between January 
2017 and June 2017 were examined to assess 
the effectiveness of this regimen compared to 
the standardized injectable-containing 
shorter regimen. Based on the analysis, WHO 
affirmed its conditional recommendation for 
the shorter all-oral bedaquiline-containing 
MDR -TB regimen to be offered as a treatment 
option to MDR -TB patients who satisfy the 
eligibility criteria. The implementation of the 
shorter all-oral bedaquiline-containing MDR-
TB regimen is expected to improve the 
programmatic management of the drug-
resistant TB component of the TB programme. 
[8,16] 
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Appendix 
 
Table 3.  Scheduled clinical & laboratory testing before, during, and after completion of the shorter all-oral 
MDR-TB treatment [8] 






Every 6 month after 
completion of treatmente 
Clinical examination 
Physical examination √ √ √ √ 
Counseling & psychosocial 
evaluation 
√ √ √ √ 
Body weight (BMI) √ √ √ √ 
Peripheral neuropathy screening √ √ √  
Vision function screening a √ √ √  
Psychiatry examination √    
Side-effect monitoring  √ √  
Microbiology test 
Sputum AFB b √ √ √ √ 
Sputum culture b √ √ √ √ 
Second-line LPA √ Repeated if AFB/ culture is positive in the 4th month 
Phenotypic DST √ Repeated if AFB/ culture is positive in the 4th month 
Laboratory, Radiology & ECG Examination 
Chest X-Ray √  √ √ 
ECG c √ √ √  
Complete Blood Count √ √ √  
Liver Function Test (ALT, AST, Bil) √ √ √  
Kidney Function Test : Ur, Cr √ √   
Electrolyte : Na, K, Cl, Mg √ √   
Uric acid √ √   
FBG & 2h PPBG d √    
TSH d √    
Pregnancy test d √    
HIV test d √    
a) Vision tests include color blindness and peripheral-field test 
b) Sputum AFB & culture test are performed every month by collecting 1 morning expelled sputum.  
At the 4th, 5th, 6th month & end of treatment, 2 consecutive morning sputum specimens are tested for AFB  
c) ECG examination are performed before treatment started, 2nd week of treatment, 1st month of treatment, and once routinely every 
month (or when there is cardiac-related complaint) 
d) Laboratory tests are performed before treatment started and repeated as indicated 
e) Monitoring after completion of treatment are performed every 6 months for 2 years, and repeated anytime symptoms of TB occur 
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Table 4.  Shorter MDR-TB regimen Anti-TB drugs side effects and monitoring requirements  [5,8,20] 
Drug name & Description Side effects Monitoring requirements & comments 
Bedaquiline (Bdq) 
A diarylquinoline antimycobacterial drug that 
inhibits ATP synthesis. 
Common: Gastrointestinal distress (nausea, vomiting, 
abdominal pain, loss of appetite); joint pain; headache. 
Less common: QT prolongation, hyperuricemia, 
phospholipidosis (the accumulation of phospholipids 
in the body’s tissues), elevated aminotransferases, 
chest pain, hemoptysis (coughing up blood). Possibly 
an increased risk of pancreatitis. 
Drug Interactions: All CYP3A4 inhibitors or inducers. 
Rifampicin (a CYP3A4 inducer) reduces bedaquiline in 
blood by half; drugs that prolong the QT interval (e.g., 
clofazimine, moxifloxacin, antifungals, and many 
others) may result in additive cardiac toxicity—their 
use is only indicated when there are no other 
alternatives; more frequent ECG monitoring is 
required. 
Monitoring: Monitor QT interval with ECG at baseline, 2, 
12, and 24 wk (more often if risk ofQT prolongation is 
present); discontinue if significant ventricular 
arrhythmia or a QTcF interval .500 msec develops; 
monitor liver enzymes every month. 
Comments: A significant imbalance in fatalities was 
noted in Trial C208 Stage 2, with a higher number of 
deaths in the bedaquiline group (10 vs. 2 in the placebo 
group; RR ¼ 5.1; P ¼ 0.017). There was no sudden 
death reported in the study. There was no discernible 
pattern for cause of deaths, and the reason for the 




Bactericidal; DNAgyrase inhibitor; renally 
excreted. 
Common: Generally well-tolerated, well-absorbed. 
Less common: Diarrhea, dizziness, gastrointestinal 
distress, headache, insomnia, photosensitivity, rash, 
vaginitis, tendonitis, psychosis, seizure (CNS effects 
seen almost exclusively in elderly). 
Monitoring: No laboratory monitoring requirements. 
Comments: Do not administer with antacids, sucralfate, 
iron, zinc, calcium, or oral potassium and magnesium 
replacements; levofloxacin, moxifloxacin have the 
most activity against M. tuberculosis. 
Clofazimine (Cfz) 
Riminophenazine; has activity in vitro but 
limited clinical evidence ofefficacy. 
Common: Orange/red discoloration of skin, conjunctiva, 
cornea, and body fluids; dry skin, pruritus, rash, 
ichthyosis, xerosis; gastrointestinal intolerance; 
photosensitivity. 
Less common: Retinopathy, severe abdominal 
symptoms, bleeding, and bowel obstruction; QT 
prolongation. 
Monitoring: Symptomatic monitoring only. 
Comments: Discolors skin and body secretions orange, 
red, or brownishblack; this should go away after 
stopping the medicine, but may take a long time; avoid 
sun; use strong sunscreens. 
Ethambutol (E)  
Bacteriostatic at conventional dosing (15 
mg/kg); inhibits lipid and cell wall metabolism; 
renally excreted. 
Common: Generally welltolerated. 
Less common: Optic neuritis, gastrointestinal distress, 
arthritis/ arthralgia. 
Monitoring: Baseline and monthly visual acuity and 
red/green color vision test when dosed at greater than 
15 mg/kg daily (10% loss is considered significant); 
regularly question patient about visual symptoms. 
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Pyrazinamide (Z) 
Bactericidal; mechanism unclear; effective in 
acidic milieu (e.g., cavitary disease, intracellular 
organisms); hepatically metabolized, renally 
excreted. 
Common: Arthritis/ arthralgias, hepatotoxicity, 
hyperuricemia, abdominal distress. 
Less common: Impaired diabetic control, rash. 
Monitoring: Baseline liver enzymes; uric acid can be 
measured if arthralgias, arthritis, or symptoms of gout 
are present. 
Comments: Usually given once daily, but can split dose 
initially to improve tolerance. 
Ethionamide (Eto) 
May be bactericidal or bacteriostatic depending 
on susceptibility and concentrations attained at 
the infection site; the carbothioamide group, 
also found on thiacetazone, and the pyridine 
ring, also found on isoniazid, appear essential 
for activity; hepatically metabolized, renally 
excreted. 
Common: Gastrointestinal distress (nausea, vomiting, 
diarrhea, abdominal pain, loss of appetite); dysgeusia 
(metallic taste); hypothyroidism (especially when 
taken with PAS). 
Less common: Arthralgias, dermatitis, gynecomastia, 
hepatitis, impotence, peripheral neuropathy, 
photosensitivity. 
Monitoring: Consider baseline liver enzymes. 
Comments: May split dose or give at bedtime to improve 
tolerability; ethionamide and prothionamide efficacies 
are considered similar; prothionamide may cause 
fewer gastrointestinal adverse effects. Consider 
thyroxine supplementation if clinical/ overt 
hypothyroid present. 
High-dose Isoniazid (HHD) 
Bactericidal; inhibits mycolic acid synthesis 
most effectively in dividing cells; hepatically 
metabolized, renally excreted 
Common: Gastrointestinal distress (nausea, vomiting, 
diarrhea, abdominal pain, loss of appetite); dysgeusia 
(metallic taste); peripheral neuropathy (dose-related; 
increased risk with malnutrition, alcoholism, diabetes, 
concurrent use of aminoglycosides, or ethionamide). 
Less common: Arthralgias, dermatitis, gynecomastia, 
hepatitis, impotence, peripheral neuropathy, 
photosensitivity. 
 
Monitoring: Consider baseline and monthly liver 
enzymes, especially if age >50 yr. 
Comments: Give with pyridoxine 50 mg/day 
 
